Dimerix Limited Announces Appointment of Dr David Fuller As Chief Medical Officer

Oct 23, 2023•over 1 year ago

Position

Chief Medical Officer

Company

Dimerix Limited

Dr David Fuller

MelbourneBiopharmaTherapeuticsPharmaceuticalBiotechnologyHealth Care

Description

Dimerix Limited announced the appointment of Dr David Fuller as Chief Medical Officer. Dr Fuller is an internationally experienced pharmaceutical executive and physician with over 30 years' experience across pre-clinical and clinical development, as well as medical and regulatory affairs, and was the former CMO of Race Oncology. Dr Fuller, who has a strong fundamental background in the Dimerix technology having worked with Dimerix prior to public listing, will be responsible for the strategic delivery of the company's flagship ACTION3 Phase 3 clinical program for focal segmental glomerulosclerosis kidney disease currently recruiting globally.

Company Information

Company

Dimerix Limited

Location

Melbourne, Victoria, Australia

About

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product, DMX-200, for kidney diseases and for respiratory complications associated with COVID-19. Dimerix has three Phase 3 clinical programs with near term value propositions 1) Global Phase 3 REMAP-CAP study in at least 200 hospitalised COVID-19 patients with respiratory pneumonia in Europe and UK 2) Multi-national Phase 3 CLARITY 2.0 study in at least 600 COVID-19 patients with respiratory complications in India 3) Global Phase 3 study in Focal Segmental Glomerulosclerosis (FSGS) patients, which is a rare kidney disease, following positive Phase 2 data in 2020 and for which Dimerix has been granted Orphan Drug Designation by the FDA and EMA Dimerix also has longer term programs in Diabetic Kidney Disease and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD).

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Dr hidden